Key result
SGLT2 inhibitors in T2D require comprehensive clinical and echocardiographic assessment to track CV status.
Why the study?
The relationship between diabetes-associated metabolic disturbances and cardiac structural and functional changes in patients with type 2 diabetes mellitus receiving SGLT2 inhibitor therapy requires comprehensive clinical and echocardiographic assessment.
Does sodium-glucose cotransporter-2 inhibitor therapy affect the structural and functional state of the heart and myocardial remodeling processes in patients with type 2 diabetes mellitus?
Does sodium-glucose cotransporter-2 inhibitor therapy affect the structural and functional state of the heart and myocardial remodeling processes in patients with type 2 diabetes mellitus?
Comprehensive clinical and echocardiographic assessment is important for evaluating cardiovascular status and remodeling in patients with type 2 diabetes mellitus receiving SGLT2 inhibitor therapy.
Answers are grounded in this paper and cite their sources.
May inform myocardial remodeling assessment in T2DM on SGLT2i; leaves open clinical implications pending prospective validation.
This article examines the structural and functional state of the heart and myocardial remodeling processes in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter-2 inhibitor therapy. Clinical and echocardiographic parameters are used to assess left ventricular structure, myocardial thickness, cardiac function, and remodeling characteristics. The study focuses on the relationship between diabetes-associated metabolic disturbances and cardiac structural and functional changes. The findings emphasize the importance of comprehensive clinical and echocardiographic assessment for evaluating cardiovascular status in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter-2 inhibitor therapy
No takes yet. Share an insight, caveat, or question.
Tursunaliyev et al. (2026) conducted a review in Type 2 diabetes mellitus. Sodium-glucose cotransporter-2 inhibitor therapy was evaluated on Left ventricular structure, myocardial thickness, cardiac function, and remodeling characteristics. Sodium-glucose cotransporter-2 inhibitor therapy in patients with type 2 diabetes mellitus necessitates comprehensive clinical and echocardiographic assessment to evaluate cardiovascular status.
Synapse has enriched 10 related papers. Consider them for comparative context: